The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: High Precision Imaging of Prostate Specific Membrane Antigen for Personalized Treatment in Prostate Cancer
Official Title: High Precision Imaging of Prostate Specific Membrane Antigen for Personalized Treatment in Prostate Cancer
Study ID: NCT03327675
Brief Summary: This is an Investigator Initiated, non-commercial, single center, non-randomized, single arm, open label pilot study on 194 patients. The patients are affected by prostate cancer but in two different clinical settings. The first group is characterized by patients who are going to be operated of radical prostatectomy and they will undergo the study imaging preoperatively. The second group experiences biochemical relapse after primary treatment.
Detailed Description: Novel, sensitive tools, such as 68Ga-PSMA PET imaging, have great potential for very early disease detection and open the possibility of early curative local salvage treatment (with surgery, radiotherapy or a combination of both). This project will moreover provide important insights into the biodistribution and dosimetry of 68Ga-PSMA, opening possibilities of 90-Yttrium or 177-Lutetium-PSMA-based radionuclidetherapy of patients with metastatic PC in the future. The study consists of 2 work units (WU): Work-unit 1: Patients at high risk for nodal involvement prior to radical prostatectomy with extended lymph node dissection Work-unit 2: Biochemical recurrence after initial treatment with curative intent
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: MALE
Healthy Volunteers: No
UZLeuven, Leuven, , Belgium
Name: Karolien Goffin, MD, PhD
Affiliation: UZ Leuven
Role: PRINCIPAL_INVESTIGATOR